MedTrace Logo

AZD6738 & Gemcitabine as Combination Therapy

NCT03669601 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2021-06-04

No results posted yet for this study

Summary

A dose escalation trial to assess the safety of AZD6738 in combination with gemcitabine in participants with advanced solid tumours.

Conditions

Interventions

DRUG

AZD6738

A potent, selective inhibitor of the serine/threonine-specific protein kinase, ataxia telangiectasia and Rad3-related protein (ATR), with good selectivity against other phosphatidylinositol 3-kinase-related kinase (PIKK) family members.

DRUG

Gemcitabine

Nucleoside metabolic inhibitor.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • CCTU- Cancer Theme

    lead OTHER

Principal Investigators

  • Duncan Jodrell · CRUK Cambridge Institute, University of Cambridge

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-15
Primary Completion
2023-09-30
Completion
2024-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03669601 on ClinicalTrials.gov